ARQL. FYI this is on ST but I cannot find a press release on it. ArQule receives EU Orphan designation for Miransertib for treatment of Proteus syndrome (through sponsor QRC Consultan…
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.